Andy Saenz Mamani

Medical oncologist

[Carlos Gonzalez @DrMedOnco]

Excited to share our randomized Phase II #SUMITBC trial, now published in @NatureComms!

Samuraciclib, a selective #CDK7 inhibitor, + fulvestrant showed promising activity in HR+/HER2− advanced #BreastCancer after CDK4/6i progression.

📊 Median PFS:
360 mg: 7.8 mo
240 mg: 8.5 mo
Fulvestrant: 5.6 mo

A particularly encouraging signal was observed in TP53 wild-type tumors with samuraciclib 360 mg:
🔹 ORR 54.5%
🔹 CBR 69.2%
🔹 mPFS 14.5 mo

These findings support further investigation of CDK7 inhibition as a strategy to overcome endocrine/CDK4/6 resistance.

Proud to be part of this international collaboration!

#BCSM #BreastCancer

🔗 https://t.co/X4RtXsOmj2

[Juan C. Díaz 🫘 @juandiaznz]

A unas semanas del 3er curso de Onconefro

🏢🏥🏢 📍 @HGM_OD es el Anfitrión

Modalidad híbrida. 👨🏻‍💻🧑🏻‍🏫

12 puntos para recertificación 🏅

Link de inscripción: https://t.co/TQJlAuChsU

Cupo limitado. ‼️

Becas disponibles a residentes de nefrología (info DM)🚨

[Inmegen México @inmegen]

Impulsa tu carrera médica con los Posgrados de Alta Especialidad del Inmegen (Ciclo 2027-2028).
👩‍⚕️👨‍⚕️Formación académica actualizada con aplicación en la práctica clínica e investigación.
🔗Más información: https://t.co/mF6TaA4bMC
#PosgradosInmegen #MedicinaGenomica #PAEMInmegen

[Gabriel Puche, MD/PhD @gabi_puchepalao]

🧵 ¿Debemos seguir haciendo angio-TC a TODOS los pacientes con cáncer y sospecha de TEP?

Un EC publicado en JAMA (Hydra Study) desafía una práctica habitual y puede cambiar nuestra aproximación diagnóstica. 👇

[Veronica Salais Michaus @MichausSalais]

With great enthusiasm we present the LATAM perspective and emerging opportunities in CRC

@OncoDailyGI
https://t.co/8VNBcUidpJ

[Dr Amol Akhade @SuyogCancer]

@Erman_Akkus @myESMO @LorenzaRimassa @DrAngelaLamarca @OncoAlert @realbowtiedoc The one which has best HR for both pfs and Os is not acceptable in many parts of the world.

[ESMO - Eur. Oncology @myESMO]

📣 ESMO #ClinicalPracticeGuideline eUpdate on #OesophagealCancer: in resectable, locally advanced oesophageal adenocarcinoma or OGJ pre- & post-operative #chemotherapy is associated with improved survival vs #Neoadjuvant #Chemoradiotherapy.

🔗 https://t.co/2uyY687G7J

[Dr Amol Akhade @SuyogCancer]

Metastatic colorectal cancer. Third line and beyond. How to treat and what's the evidence. Nice review in @NatRevClinOncol

[Nature Reviews Cancer @NatureRevCancer]

#Chromothripsis leads to the acquisition of multiple genomic aberrations. Simovic-Lorenz & Ernst (@DKFZ) discuss mechanistic models of chromothripsis, outline its role in cancer development + tumour evolution & suggest therapeutic vulnerabilities.

📖👇
https://t.co/gIdJxkR3Sj

[Yakup Ergün @dr_yakupergun]

#ASCO23
Prognosis and trends in chemotherapy use for patients with stage IA TNBC: A population-based study

📌Chemotherapy significantly improved BCSS in pts with T1c TNBC (Δ3.3%), but not for pts with T1b

From the excellent presentation of Dr. @PTarantinoMD

@OncoAlert

[Christine Lovly, MD, PhD, FASCO @christine_lovly]

Major update for small cell #lung cancer! #LCSM

With @juliensage + @FoundationATCG, our paper now on @bioRxiv:

►Genomic analysis of *3,600* pts with SCLC; largest SCLC study to date!

►Multiple interesting findings discussed in this 🧵
https://t.co/zkLKyDgBkf

[Yüksel Ürün @DrYukselUrun]

🧬🧬🧬Universal Germline and Tumor Genomic Testing in #Cancer care
It has the potential to revolutionize personalized medicine and improve patient outcomes. Exciting times in the world of genomics! #cancerresearch @OncoAlert #MedTwitter @VivekSubbiah @Dr_R_Kurzrock @ASCO @myESMO

[Alan Reyes-M.D @dralanreyesonco]

NeoAdyuvancia en CÁNCER DE COLON (FOX-TROT) sale a luz. FOLFOX 4 ciclos —CX —-> FOLFOX 8 ciclos

[Hegel Hernandez @Hegel_MD_PhD]

🤔#artificialintelligence in early pan-#cancer detection is getting closer! #GIPXplore

🤯by analyzing DNA, AI can identify mutations, fragmentomic #GIPXplore & methylomic paterns, that may increase risk or detect early cancer, leading to targeted prevention & early intervention

[jpedrokessner @KessnerJp]

Lung Cancer Screening: The Lancet review.
https://t.co/cmm9MIfzL9
🚬🫁🦀🎞⏳️🧐📚
@TheLancet @ALATorax @atscommunity @RadiologyACR @accpchest @ACCP @ERSpublications @SPLF_SocPneumo @SeparRespira @socapnet @NeumoMadrid @DGPneumologie @RespirologyAPSR @LungCancerEu

[International Lung Cancer Summit @LungSummit]

#LungCancer continues to be a leading cause of death worldwide 🌎

Learn more about the disease, its risk factors, and more with us over this #LungCancerAwarenessMonth 🫁

[Dr Sarah Sammons @drsarahsam]

PADA-1 was a monumental effort.

1017 enrolled on AI/CDK
279 (27%) rise in ESR1 mutations
69/279 (25%) with concurrent progression on scans
172/279 without progression on scans randomized to switch versus stay

[Arndt Vogel @ArndtVogel]

🔥MSI testing in #CRC 🔥
https://t.co/YKqpkcrkzo
in Clinical Colorectal Cancer
👉No Surprises...

✅<50yrs: 12% MSI; 1.5% mBRAF
✅>50yrs: 21% MSI; 16.1% mBRAF

👉 MSI testing in elderly population, do not forget...
🎯KEYNOTE-177, CHECKMATE-142, NICHE-2...

@myESMO @OncoAlert

[Corinne Faivre-Finn @finn_corinne]

Wonderful effort @JulienSage @christine_lovly and team

[Pashtoon Kasi MD, MS @pashtoonkasi]

One of the most important findings unveiled @ESMOWorldGI.

🎯 #HER2⛔️in #ColorectalCancer

#Mountaineer🏔study with
💊 TUCATINIB➕TRASTUZUMAB

✅New Standard of Care
OS~2 years!

Ecstatic to have contributed to a new option.
🙏🏽 patients. #CRCSM

#WCGIC2022 @myESMO @OncoAlert